The Expanding Frontier of Targeted Protein Degradation: Translational & Clinical Advances in Neurology & Immuno-Oncology

• Clinical biomarker data from LRRK2 program informing target engagement and pharmacology
• Emerging data in polyQ-AR and HPK1 programs highlighting early signs of broader applicability across neurological and immuno-oncology targets
• Foundational overview of PROTAC degrader design and mechanism

Speakers:

Adam Hendricson

Associate Director of Neuroscience

Arvinas, Inc.